Abstract: Systems and methods are provided for using a gesture detected at a wrist-wearable device to cause presentation of camera data at a head-wearable device. One example method includes receiving, via one or more sensors of a wrist-wearable device worn by a user, data generated based on performance of an in-air hand gesture by the user. In accordance with a determination that the data indicates that the in-air hand gesture is a camera-control gesture, the method further includes causing presentation to the user, via a display of a head-wearable device that is worn by the user and that is in communication with the wrist-wearable device, of a representation of camera data from a camera that is in communication with one or both of the wrist-wearable device and the head-wearable device.

Abstract: Compositions and methods for regulating immunometabolism and preventing and/or treating interferon-driven inflammation, including anti-inflammatory agents which upregulate fumarate hydratase enzymatic activity and/or expression of fumarate hydratase protein, and methods for preventing and/or treating inflammation in a patient in need thereof, wherein the methods comprise: administering an effective amount of a fumarate hydratase modulating agent to the patient.

Abstract: The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.

Abstract: Electrolytic interior surface treatment apparatus (100) for the electrolytic treatment of an internal surface (102) of a metallic pipe (1) includes at least two oppositely polarised electrodes (3, 4). The apparatus (100) includes: an electrically insulating centralisation arrangement (106) to keep, in use, the electrodes (3, 4) centred within the pipe (1); and an electrically insulating flexible connection arrangement (104) located between the two electrodes (3, 4) to permit movement of one electrode relative to the other. The centralisation arrangement (106) includes a plurality of spaced apart centralisation devices (5, 6). Each centralisation device (5, 6) includes an electrically insulating mounting (7) for mounting the respective centralisation device (5, 6) to the apparatus (100). Each centralisation device (5, 6) includes a plurality of flexible elements (108), each of which is fixed to the mounting (7) and extends outwardly from the mounting (7).

Abstract: The invention provides electrochemical surface treatment apparatus (100) for the treatment of radioactively contaminated internal surfaces of a pipe (1). The apparatus (100) includes an electrode device (102). The device (102) includes an electrode (4), which, in use, is located in electrolyte liquid (2) within the pipe (1) adjacent a treatment surface (104) to be treated with a gap (106) defined between the electrode (4) and the treatment surface (104). The apparatus (100) includes a circulation arrangement (108). The electrode (4) defines an internal passage (110). In use, the circulation arrangement (108) causes a recirculating flow of electrolyte liquid (2) through the gap (106) in one direction and along the passage (110) in an opposite direction.

Abstract: The various implementations described herein include methods and systems for using hand gestures detected at a wearable device to navigate a user interface. An example method includes receiving, via one or more neuromuscular-signal sensors of a wrist-wearable device worn by a user, data generated during performance of an in-air wrist movement by a wrist of the user. The method also includes moving a point of focus on the user interface in accordance with the in-air wrist movement; and receiving, via the one or more neuromuscular-signal sensors, additional data generated during performance of an in-air gesture by the user. The method further includes determining that the in-air gesture is an execution gesture; and executing a command corresponding to the execution gesture.

Abstract: The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts, solvates and prodrugs thereof: wherein Q is selected from O, S and Se; J is S or Se; W1 and W2, when present, are independently selected from N and C; R1 and R2 are independently selected from the group consisting of hydrogen, C1-C12 alkyl, C2-C12 alkenyl, C2-C12 alkynyl, aryl, heterocyclyl, heteroaryl, cycloalkyl, cycloalkenyl, amino, amido, alkylthio, acyl, arylalkyl and acylamido, all of which may be optionally substituted; and wherein at least one of W1 and W2 is present and is a nitrogen atom and when R1 or R2 are cyclic then the respective W1 or W2 may form part of the ring structure. The present invention also relates to pharmaceutical compositions including such compounds, to methods of treatment using such compounds, in particular in relation to NLRP3 inflammasome mediated disorders, and to associated diagnostic uses.

Abstract: The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.

Abstract: The present invention relates to compounds of formula (I): wherein Q is O or S; R1 is a cyclic group substituted with at least one group X, wherein R1 may optionally be further substituted; X is any group comprising a carbonyl group; and R2 is a cyclic group substituted at the ?-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the dual action of NLRP3 inhibition and the stimulation of insulin secretion.

Abstract: Systems and methods are provided for using a gesture detected at a wrist-wearable device to cause presentation of camera data at a head-wearable device. One example method includes receiving, via one or more sensors of a wrist-wearable device worn by a user, data generated based on performance of an in-air hand gesture by the user. In accordance with a determination that the data indicates that the in-air hand gesture is a camera-control gesture, the method further includes causing presentation to the user, via a display of a head-wearable device that is worn by the user and that is in communication with the wrist-wearable device, of a representation of camera data from a camera that is in communication with one or both of the wrist-wearable device and the head-wearable device.

Abstract: The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.

Abstract: The present invention is directed to compositions and methods for the treatment of degenerative retinal conditions. According to a general aspect, the present invention is directed to inflammatory mediators, preferably components or substrates of the NLRP3-inflammasome, for use in the treatment of degenerative retinal conditions involving drusen and anaphylatoxin-induced choroidal-neovascularisation. The invention is also directed to a method for the treatment of degenerative retinal conditions involving drusen and anaphylatoxin-induced choroidal-neovascularisation and to recombinant vectors and recombinant proteins for use in such methods. The present invention also provides a method for determining the risk of developing or monitoring the progression of diseases involving drusen and anaphylatoxin-induced choroidal neo-vascularisation.

Abstract: An electrolytic treatment system to decontaminate the surface of a radioactively contaminated metallic workpiece has at least two electrodes in close proximity to the surface but not in direct electrical contact. The electrodes are separated from the surface by an electrolyte. Insulation is provided in the electrolyte between the electrodes to avoid or minimize a direct current path between the electrodes though the electrolyte.

Abstract: The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.

Abstract: The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts, solvates and prodrugs thereof: wherein Q is selected from O, S and Se; J is S or Se; W1 and W2, when present, are independently selected from N and C; R1 and R2 are independently selected from the group consisting of hydrogen, C1-C12 alkyl, C2-C12 alkenyl, C2-C12 alkynyl, aryl, heterocyclyl, heteroaryl, cycloalkyl, cycloalkenyl, amino, amido, alkylthio, acyl, arylalkyl and acylamido, all of which may be optionally substituted; and wherein at least one of W1 and W2 is present and is a nitrogen atom and when R1 or R2 are cyclic then the respective W1 or W2 may form part of the ring structure. The present invention also relates to pharmaceutical compositions including such compounds, to methods of treatment using such compounds, in particular in relation to NLRP3 inflammasome mediated disorders, and to associated diagnostic uses.

Abstract: The present invention relates to compounds of formula (I): wherein Q is O or S; R1 is a cyclic group substituted with at least one group X, wherein R1 may optionally be further substituted; X is any group comprising a carbonyl group; and R2 is a cyclic group substituted at the ?-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the dual action of NLRP3 inhibition and the stimulation of insulin secretion.

Abstract: An isolated protein from Cimex lectularius comprising an amino acid sequence selected from any one of SEQ ID No. 1 or 5 or fragment thereof or an isolated polypeptide from Cimex lectularius comprising an amino acid sequence selected from any one or more of SEQ ID No. 2, SEQ ID No. 3, SEQ ID No. 6 and SEQ ID No. 7 or fragment thereof for use in generating antibodies to detect the presence of antigens specific for Cimex lectularius wherein the antibodies are capable of detecting Cimex lectularius antigen in all stages of Cimex lectularius development from egg, nymphs, moults to mature male and female adults at antigen concentrations of less than 20 ?g/m1.

Abstract: The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.

Abstract: The present invention provides for certain sulfonyl ureas and related compounds which have advantageous properties and show useful activity in the inhibition of activation of the NLRP3 inflammasome. Such compounds are useful in the treatment of a wide range of disorders in which the inflammation process, or more specifically the NLRP3 inflammasome, have been implicated as being a key factor.

Abstract: The present invention is directed to compositions and methods for the treatment of degenerative retinal conditions. According to a general aspect, the present invention is directed to inflammatory mediators, preferably components or substrates of the NLRP3-inflammasome, for use in the treatment of degenerative retinal conditions involving drusen and anaphylatoxin-induced choroidal-neovascularisation. The invention is also directed to a method for the treatment of degenerative retinal conditions involving drusen and anaphylatoxin-induced choroidal-neovascularisation and to recombinant vectors and recombinant proteins for use in such methods. The present invention also provides a method for determining the risk of developing or monitoring the progression of diseases involving drusen and anaphylatoxin-induced choroidal neo-vascularisation.